discontinue sulfonylurea when starting glp-1 receptor agonist Sulfonylureas 4. Practical Considerations for Integrating

Obes Rev 23(6):e13435 Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD (2022) Adverse drug reactions of GLP-1 agonists: a systematic review of case reports

Funding support provided by Health Canada

Early Clinical Results: In two small clinical studies, GLP-1 agonists reduced alcohol consumption and craving in patients with alcohol use disorder and reduced opioid craving by 40% among opioid use disorder patients 5 Bajaj, S

Individual responses to the starting dose vary enormously

6 , e13685 (2018) S.H

Thus, patients taking the agents associated with the greatest weight loss, tirzepatide and semaglutide, have the highest incidence of developing both hypocalcemia and hypercalcemia